<DOC>
	<DOCNO>NCT02382666</DOCNO>
	<brief_summary>The purpose study assess safety tolerability single increase dos intravenously administer rolapitant healthy male female subject .</brief_summary>
	<brief_title>A Phase 1 , 2-Part , Single Ascending Dose Assessment Safety , Tolerability , Pharmacokinetics Rolapitant Intravenous Healthy Volunteers</brief_title>
	<detailed_description>Part 1 study design evaluate safety tolerability SAD , 6 cohort , rolapitant IV ( 2 mg/mL solution ) administer IV infusion 30 minute . In Part 2 study , safety tolerability high safe well-tolerated dose establish Part 1 evaluate expand cohort . The high safe well-tolerated dose establish Part 1 ascertain follow criterion : upper limit 90 % confidence interval ( CI ) Cmax . A minimum 40 subject enrol Part 2 .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>8- ( ( 1- ( 3,5-bis ( trifluoromethyl ) phenyl ) ethoxy ) methyl ) -8-phenyl-1,7-diazaspiro ( 4,5 ) decan-2-one</mesh_term>
	<criteria>Main Subject must healthy male female age 18 55 year Screening A female subject must negative pregnancy test Screening Day 1 . A female subject childbearing potential must agree use accepted method birth control ( exclude hormonal birth control method ) Screening 30 day final study drug administration . Subject must body mass index ( BMI ) 18.5 32.0 kg/m2 weight â‰¥ 50 kg Screening . Subject must able provide inform consent risk benefit explain . Subject must also willing able comply protocol requirement . Subject must general good health determine Investigator base prestudy medical , medication , surgical history ; physical examination ; clinical laboratory test . Main Subject must dose test drug blind study drug another investigational study within 30 day 5 halflives biologic activity test drug , whichever longer , time first study dose . Subject must history hypersensitivity rolapitant IV excipients complete study visit part previous rolapitant study within 6 month prior first study drug administration ( Day Subject must poor venous access consider venipuncture intolerable . Subject must history significant complication anxiety associate IV administration medication , opinion Investigator , could make subject unable complete dosing requirement . Subject must pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>